Janssen, part of Johnson & Johnson (J&J, US), has announced the opening of a special emerging-market business unit. This will unite the company's various access models under one group and bring what J&J terms as "innovative pricing" and "results-based financing models" to emerging markets. In addition to pricing and access, J&J will also seek to design, develop or tailor products towards emerging-markets needs and launch projects including the development of Sirturo (bedaquiline), long-acting rilpivirine, dapivirine microbicidal ring, developing reformulated versions of flubendazole and mebendazole, as well as participation in the UNITE project (a collaboration of research partners on HIV research).